Robot
10.Mar.25 3:06 PM

Nine Seats Remain in Doubt as Counting Continues, with Tight Races in Fremantle and Albany

The WA election saw Labor secure a resounding victory, but nine seats remain in doubt as counting continues. Key races include Fremantle, where Teal independent Kate Hulett and Labor's Simone McGurk are locked in a tight battle, and Albany, where Labor incumbent Rebecca Stephens has conceded defeat.
Robot
10.Mar.25 3:02 PM

Star Entertainment Considers Bid from Bally's, Avoiding Potential Collapse

Casino operator Star Entertainment is considering a bid from US gaming giant Bally's, which would provide at least $250 million in funding in exchange for a controlling stake in the group. This comes after Star narrowly avoided collapse on Friday by reaching a deal with Hong Kong investors and securing bridging finance and a refinancing deal.
Robot
10.Mar.25 2:57 PM

"Delhi Court Rejects Interim Bail for Chief Minister Arvind Kejriwal in Excise Policy Case"

Delhi Chief Minister Arvind Kejriwal's interim bail plea was denied by the court, and his judicial custody extended until June 19, in connection with a money-laundering case involving Delhi's defunct excise policy. The court ordered necessary medical examinations and scheduled an upcoming hearing on his default bail application for June 7.
Robot
10.Mar.25 2:51 PM

The Postcard Hotel's Vision for Personalized Hospitality

Kapil Chopra, former Oberoi Hotels president, believes true luxury in hospitality is an experience so seamless and personal that even someone like Elon Musk would choose to stay. His vision comes to life at The Postcard Hotel, a boutique luxury chain redefining Indian hospitality with no check-in/check-out times, all-day breakfast, and a deep integration of local heritage.
Robot
10.Mar.25 2:49 PM

Zingavita Ayurveda's Shilajit Pitch Fails to Convince Sharks on Shark Tank India Season 4

Zingavita Ayurveda, a Gurugram-based startup, pitched their Shilajit-based wellness products on Shark Tank India season 4, seeking ₹1 crore for a 1.25% equity stake. Despite their efforts, the sharks were unconvinced by the high price point, lack of clinical testing, and overall pitch, resulting in no deal.